Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Cathinone derivatives

α-PHiP

C16H23NO CAS 2181620-71-1 Analytical reference material — not for human consumption
α-PHiP, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
α-PHiP
IUPAC name
4-methyl-1-phenyl-2-pyrrolidin-1-ylpentan-1-one
Parent CAS number (reference)
2181620-71-1
Molecular formula
C16H23NO
Molecular weight
245.36 g/mol
InChIKey
UOZWZANRCOALQL-UHFFFAOYSA-N
PubChem
CID 59809191
Source
PubChem
Verified synonyms & catalog abbreviations
alpha-PIHP alpha-PHiP alpha-Pyrrolidinoisohexaphenone αPHiP α PHiP a-PHiP aPHiP a-PiHP

Verified Neurochemical & Toxicological Intelligence

alpha-PiHP (alpha-Pyrrolidinoisohexanophenone / alpha-PHiP)

Potent Stimulant (DAT-Selective NDRI) Substituted cathinone / Pyrrolidinophenone (branched isohexanophenone isomer of alpha-PHP)
Verified PubChem & CAS Identity C16H23NO · CAS 2181620-71-1 · CID 59809191
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 245.37 g/mol
Peer-Reviewed & Agency Citations 3 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

Branched acyl-chain positional isomer of alpha-PHP (4-methylpentan-1-one backbone, distinct from ring-methylated MPHP) acting as a pure, catecholamine-selective monoamine transporter blocker (NDRI) without releasing activity. WHO 45th ECDD data show pronounced selectivity for DAT (IC50 = 16.5 nM, Ki = 35.7 nM — ~12-fold more potent at uptake blockade and ~16-fold higher affinity than cocaine) and NET (IC50 = 41.4 nM, Ki = 340 nM) while sparing SERT (IC50 > 10,000 nM, Ki > 7,500 nM). High DAT selectivity drives an intense dopaminergic rush and extreme repeated exposure compulsivity.

Biotransformation & Active Metabolites

Expected to follow related pyrrolidinophenone pathways (keto reduction, oxidations, and N-dealkylation); WHO 45th ECDD notes no controlled human clinical pharmacokinetic studies exist.

Temporal Pharmacokinetics

Sharp, intensely reinforcing dopaminergic stimulant producing rapid mood elevation, ego inflation, thought acceleration, and heightened libido alongside a very narrow margin before agitation and paranoia.

  1. Onset 30–60 minutes oral (1–2 minutes mucosal; ~1 minute vaporized)
  2. Peak Window 1–2 hours oral (20–45 minutes mucosal)
  3. Total Window 2–5 hours oral (2–4 hours mucosal; 1–3 hours vaporized)
  4. Residual / Half-Life 6–12 hours of residual wakefulness, vasoconstriction, and insomnia across all routes; formal human plasma half-life is unverified.

Active at 3–5 mg orally and 1–3 mg mucosal. Because its intense DAT-driven rush subsides within 2–5 hours while leaving 6–12 hours of residual cardiovascular and adrenergic stimulation, alpha-PiHP triggers relentless compulsive repeated exposure—rapidly escalating into acute paranoid psychosis, severe vasoconstriction, hyperthermia, rhabdomyolysis, and documented single-substance fatalities.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
3–5 mg oral (mucosal: 1–3 mg; vaporized: 1–2 mg)
Cognitive & Sensory

Immediate crisp alertness, subtle focus intensification, and reduced fatigue.

Somatic & Autonomic

Slight heart-rate elevation and appetite suppression.

Light
5–15 mg oral (mucosal: 3–10 mg; vaporized: 2–10 mg)
Cognitive & Sensory

Clear dopaminergic mood lift, talkativeness, task fixation, and confident energy.

Somatic & Autonomic

Moderate pulse and blood-pressure increase, dry mouth, and light sweating.

Common Reference
15–30 mg oral (PMC11051472 10–30 mg; mucosal: 10–25 mg; vaporized: 10–20 mg)
Cognitive & Sensory

Powerful mood-elevating rush, ego inflation, disinhibition, rapid thought acceleration, and strong urge to redose.

Somatic & Autonomic

Marked tachycardia, hypertension, cold extremities from vasoconstriction, jaw tension, and dry mucous membranes.

Strong
30–50 mg oral (mucosal: 25–40 mg; vaporized: 20–30 mg)
Cognitive & Sensory

Compulsive repeated exposure fixation, hyper-vigilance, severe anxiety, logorrhoea, and emerging paranoid ideation.

Somatic & Autonomic

Strong peripheral vasoconstriction, tremors, bruxism, dehydration, and rapid heart rate.

Heavy / Toxic Zone
50+ mg oral (mucosal: 40+ mg; vaporized: 30+ mg)
Cognitive & Sensory

Severe paranoid psychosis, hallucinations, disorientation, delirium, or sudden loss of consciousness.

Somatic & Autonomic

Extreme tachycardia and hypertension, hyperthermia, rhabdomyolysis, respiratory alkalosis, and fatal cardiac arrest.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

16.5 nM DAT and 41.4 nM NET blockade under MAO inhibition triggers rapid, fatal hypertensive crisis and cardiac arrhythmia.

Other stimulants and vasoconstrictors (Cocaine, alpha-PVP, alpha-PHP, MDPHP, NEP, Hexen, MDMA, 25x-NBOMe)

Extreme additive catecholaminergic cardiotoxicity, coronary vasospasm, hyperthermia, and convulsions.

Tramadol and Opioids

Tramadol precipitates seizures; opioids risk fatal delayed respiratory arrest once alpha-PiHP's short 2–4 hour peak drops off.

Elevated Hazard — Avoid

Alcohol, Benzodiazepines, Synthetic Cannabinoids, and GHB/GBL

Stimulation masks depressant intoxication until sudden collapse; polydrug combinations feature prominently in European post-mortem alpha-PiHP cases.

Dissociatives (3-MeO-PCP, O-PCE) and Psychedelics

Severely compounds risk of acute delusional mania, panic, and erratic behavioral emergencies.

Caution / Receptor Attenuation

Cannabis

Frequently triggers acute paranoia, hallucinations, and spike in heart rate.

Caffeine

Adds peripheral tremors, tachycardia, and vasoconstriction.

Structural Isomer & Sibling Comparison

alpha-PiHP is the branched acyl-chain isomer of alpha-PHP (both C16H23NO, 245.37 g/mol). Compared to alpha-PVP and alpha-PHP, alpha-PiHP displays higher DAT-over-NET selectivity (DAT IC50 16.5 nM vs. NET 41.4 nM) and a shorter primary plateau (2–5 h oral vs. 2–8 h for alpha-PHP), but carries equally fierce—or stronger—anecdotal repeated exposure compulsivity. It is ~10-fold more potent at DAT than NEP.

Physicochemical Stability & Storage

Physical Form: Odorless white to off-white crystalline solid, fine powder, or rock-like crystal chunks as the monohydrochloride salt (MW 281.8 g/mol). · Soluble in water and PBS (pH 7.2, ~10 mg/mL), DMSO (~5 mg/mL), DMF (~3 mg/mL), ethanol (~3 mg/mL), and methanol (~1 mg/mL).

Store tightly sealed in a cool, dry, light-resistant container.

Cross-Tolerance & Dependence Profile

Extremely high psychological addiction and binge-compulsion liability. Rapid acute tolerance within hours; cross-tolerant with alpha-PVP, alpha-PHP, MDPHP, NEP, and cocaine (halving in 3–7 days, baseline in 1–2 weeks). Multi-day binges reliably provoke stimulant psychosis.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
DAT Dopamine transporter

DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.

NET Norepinephrine transporter

NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.

SERT Serotonin transporter

SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.

SNDRA / NDRI Releaser or reuptake blocker

An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

5-HT ↑↑ Serotonergic Overload (Serotonin Toxicity)

A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.

HR / Naczynia Vasoconstriction & Cardiovascular Load

Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.

Comprehensive Analytical & Toxicological Monograph

alpha-PiHP (alpha-pyrrolidinoisohexanophenone / alpha-PHiP; 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one; freebase CAS 2181620-71-1, hydrochloride CAS 2705245-60-7, PubChem CID 59809191) is a branched-chain pyrrolidinophenone cathinone supplied as pure analytical crystalline powder or crystals (C16H23NO, 245.37 g/mol). Chemically, it is the branched isohexanophenone chain isomer of alpha-PHP (distinct from ring-methylated MPHP). According to the WHO 45th ECDD Critical Review, alpha-PiHP functions as a pure, catecholamine-selective monoamine transporter blocker without substrate-releasing activity, inhibiting dopamine reuptake at IC50 = 16.5 nM (~12-fold more potent than cocaine) and norepinephrine reuptake at IC50 = 41.4 nM while sparing serotonin reuptake (SERT IC50 > 10,000 nM). Calibrated milligram or volumetric measurement is essential: WHO-compiled oral brackets place threshold effects at 3–5 mg, light stimulation at 5–15 mg, common mood-elevating stimulation at 15–30 mg, strong intensity at 30–50 mg, and heavy overdose risk above 50 mg (mucosal common range is 10–25 mg; vaporized 10–20 mg, with ~1 minute onset and extreme repeated exposure hazard). Oral effects begin in 30–60 minutes and last 2–5 hours (mucosal 2–4 hours), followed by 6–12 hours of residual wakefulness and vasoconstriction. Because the dopaminergic rush fades rapidly relative to adrenergic after-effects, repeated repeated exposure swiftly precipitates sleep deprivation, severe paranoia, rhabdomyolysis, and documented single-substance fatalities. Compared to alpha-PVP and alpha-PHP, alpha-PiHP is slightly shorter-acting and more DAT-selective, while remaining ~10x stronger at DAT than NEP. Never combine alpha-PiHP with MAOIs, cocaine, other cathinones, tramadol, opioids, GHB/GBL, or 25x-NBOMe.

Chemical Architecture & Structural Profile

α-PHiP (4-methyl-1-phenyl-2-pyrrolidin-1-ylpentan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C16H23NO and a molar mass of 245.36 g/mol. The parent molecule is indexed under CAS registry number 2181620-71-1 and in the NCBI PubChem database as CID 59809191 (Standard InChIKey: UOZWZANRCOALQL-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PHiP is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations